<DOC>
	<DOCNO>NCT03070015</DOCNO>
	<brief_summary>The primary purpose study ( Part A ) ass change body weight body circumference parameter achievable 4 week Nutrisystem program compare self-directed diet ( i.e . Dietary Approaches Stop Hypertension DASH ) . In Part B , subject Nutrisystem program give option continue program another 8 week .</brief_summary>
	<brief_title>The Effects Commercially Available Weight Loss Program Body Weight Overweight Men Women</brief_title>
	<detailed_description>A randomize , control , parallel study design two part ( Part A Part B ) . Study visit include Screening , Randomization , Weeks 1 , 2 , 3 4 . Week 4 serf also closeout study visit Part A . Subjects randomized intervention group ( i.e. , Nutrisystem group ) continue program additional 8 week , include additional study visit week 8 12 . Eighty-four ( N=84 ) healthy men woman , match pair BMI , randomize one two group 28 day ( 4 week ) : Nutrisystem program self-directed Dietary Approaches Stop Hypertension ( `` DASH '' ) . All subject Nutrisystem group complete Part A continue Nutrisystem program additional 8 week ( Part B ) . Daily energy intake target group include 1000 kcal/day diet woman men first week . After first week woman follow 1200 kcal/day diet men follow 1500 kcal/day diet . Subjects BMI &gt; 40 add approximately 200 additional calorie diet day . Body weight body circumference ( Waist , Hip , Chest , Arm &amp; Thigh Sum 5 ) measure obtain baseline week 1 , 2 , 3 , 4 ( Part A ) . And week 8 12 Nutrisystem group ( Part B ) .</detailed_description>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<criteria>Subject male female , 1970 year age , inclusive . Subject BMI 25.00 44.99 kg/m2 Screening visit . Subject nonsmoker . Female study participant age 1949 must steady dose oral contraceptive ( OCA ) [ reduce weight variability secondary change occur luteal phase menses ] . Stable dose define dose least past 90 day . Female study participant 50 currently birth control weight stable least prior three month enrol . Subject willing follow study program instruction , include avoidance nonstudyrelated food beverage . Subject willing able comply visit schedule . Subject agree follow instruction meal plan per randomization Nutrisystem SelfDirected . Subject agree follow physical activity recommendation outline plan . If premenopausal female , subject history regular menstrual cycle range length 21 35 , applicable . Judged good health basis medical history screen laboratory assessment . Subject understands study procedure sign form provide informed consent participate study authorization release relevant protect health information study Investigators . Females prior diagnosis premenstrual syndrome Premenstrual dysphoric disorder ( PMDD ) . Subject abnormal laboratory test result clinical significance Screening visit upon retesting normalize ( per physician discretion ) . Subject weight loss gain ≥10 lb ( 4.5 kg ) three ( 3 ) month prior Visit 1 ( Week 1 ) . Subject use weight loss medication within past three month Screening visit . Subject dietary tendency may representative disordered eating ( opinion Investigator ) . Subject know allergy , sensitivity , intolerance study food ingredient study menu provide . Subject previously diagnose diabetes mellitus ( type 1 type 2 ) fast glucose ≥126 mg/dL screen visit . Subject thyroid medication dose consider stable . Stable dose consistently least 90 day . Subject used prescription weight loss medication within three month prior Screening Visit , dietary supplement program intend alter body weight within last four week . Subject use hypoglycemic medication ( without diagnosis diabetes , e.g . metformin PCOS exclusionary ) dietary supplement may affect carbohydrate metabolism . Subject use prescription Corticosteroids ( oral systemic ) within past three month . Subjects use medication dietary supplement likely markedly affect appetite metabolic rate ( e.g. , betablockers ) may exclude , base judgment Investigator ( washout prior study randomization ) . Subject history presence clinically important cardiac , renal , hepatic , endocrine , pulmonary , biliary , pancreatic , neurologic disorder . Subject active gastrointestinal disorder peptic ulcer disease malabsorption syndrome ( mild lactose intolerance gastroesophageal reflux diseases acceptable ) . Subject active infection sign/symptoms infection . The randomization visit reschedule allow subject symptomfree type systemic infection least 5 day . Subject history gastrointestinal surgery know affect nutrient absorption body weight . Subject uncontrolled hypertension ( systolic blood pressure ≥160 mm Hg diastolic blood pressure ≥100 mm Hg ) define blood pressure measure Screening visit . Subject history presence cancer prior 5 year , except nonmelanoma skin cancer . Subject female pregnant , plan pregnant study period , lactating , childbearing potential unwilling commit use medically approve form contraception ( doublebarrier method ) throughout study period . The method contraception must record source document . Subject premenopausal female use form hormonal contraception result normal menstrual cycle , include regular menses period . Subject recent history ( within 12 month Visit 1 , Week 1 ) strong potential alcohol substance abuse . Alcohol abuse define &gt; 14 drink per week ( 1 drink = 12 oz beer , 5 oz wine , 1½ oz distil spirit ) . Subject hospitalize within past oneyear mental emotional illness . Exposure nonregistered drug product within 30 prior screen visit . Individual condition Investigator believe would interfere ability provide inform consent , comply study protocol , might confound interpretation study result put person undue risk .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Weight Loss</keyword>
	<keyword>Obesity</keyword>
	<keyword>Overweight</keyword>
</DOC>